- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04931771
Fractional Flow Reserve or 3D-Quantitative-Coronary-Angiography Based Vessel-FFR Guided Revascularization (FAST III)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The FAST III is a randomized controlled, open-label, multicenter, international, non-inferiority, strategy trial of a vFFR guided strategy as compared to a FFR guided strategy to guide coronary revascularization in 2228 subjects with intermediate coronary artery lesions.
Patients are screened for inclusion/exclusion criteria after the indication for coronary catheterization is established. After providing informed consent, patients are enrolled. Randomization is performed in the randomization module of the EDC system with an allocation ratio of 1:1 and stratification by center. The primary endpoint is a composite of all-cause death, any myocardial infarction, or any revascularization at 1 year post-randomization.
All deaths and major cardiovascular events, including the individual components of primary and secondary endpoints are adjudicated by an independent Clinical Events Committee (CEC), using standardized definitions. An independent Data and Safety Monitoring Board (DSMB) will formally review the accumulating data to ensure there is no avoidable increased risk for harm to participants. The FAST III trial is performed in accordance with the Declaration of Helsinki, Good Clinical Practice (GCP), ISO 14155:2020, EC requirements and country specific regulations.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Ernest Spitzer, MD
- Phone Number: +31102062828
- Email: E.Spitzer@ECRI-Trials.com
Study Contact Backup
- Name: Monique Schuijer, PhD
- Phone Number: +31102062828
- Email: MSchuijer@cardialysis.nl
Study Locations
-
-
-
Caen, France
- Recruiting
- Clinique St Martin
-
Principal Investigator:
- Jean Fancois Morelle, MD, PhD
-
Grenoble, France
- Not yet recruiting
- Institut Cardiovasculaire de Grenoble
-
Principal Investigator:
- Benjamin Faurie, MD, PhD
-
Lille, France
- Recruiting
- CHU Lille - Institut Coeur Poumon
-
Principal Investigator:
- Eric van Belle, MD, PhD
-
Lyon, France
- Recruiting
- Hôpital de la Croix Rousse, Hospices Civils de Lyon
-
Principal Investigator:
- Brahim Harbaoui, MD, PhD
-
Massy, France
- Not yet recruiting
- Hôpital privé Jacques Cartier
-
Principal Investigator:
- Thomas HOVASSE, MD, PhD
-
Melun, France
- Recruiting
- Clinique les Fontaines
-
Principal Investigator:
- Patrick Dupouy, MD, PhD
-
Rouen, France
- Recruiting
- Clinique Saint Hilaire
-
Principal Investigator:
- Matthieu Godin, MD, PhD
-
-
-
-
-
Bad Oeynhausen, Germany
- Recruiting
- Herz- und Diabeteszentrum NRW
-
Principal Investigator:
- Regine Brinkmann, MD, PhD
-
Berlin, Germany
- Recruiting
- Unfallkrankenhaus Berlin
-
Principal Investigator:
- Steffen Bohl, MD, PhD
-
Berlin, Germany
- Recruiting
- Charité- Campus Benjamin Franklin
-
Principal Investigator:
- Ulf Landmesser, MD, PhD
-
Düsseldorf, Germany
- Not yet recruiting
- Universitätsklinikum Düsseldorf
-
Principal Investigator:
- Georg Wolff, MD, PhD
-
Neuwied, Germany
- Recruiting
- Marienhaus Klinikum
-
Principal Investigator:
- Burkhard Huegl, MD, PhD
-
Völklingen, Germany
- Recruiting
- SHG Klinik Völklingen
-
Principal Investigator:
- Fernando Gatto, MD, PhD
-
-
-
-
-
Cork, Ireland
- Recruiting
- Mater Private Cork
-
Principal Investigator:
- Ronan Margey, MD, PhD
-
Dublin, Ireland
- Recruiting
- Mater Private Dublin
-
Principal Investigator:
- Robert Byrne, MD, PhD
-
Dublin, Ireland
- Withdrawn
- Beaumont Hospital
-
Dublin, Ireland
- Recruiting
- St James Hospital
-
Principal Investigator:
- John Cosgrave, MD, PhD
-
-
-
-
-
Bergamo, Italy
- Recruiting
- Azienda Ospedaliera Papa Giovanni XXIII
-
Principal Investigator:
- Paolo Canova, MD, PhD
-
Cona, Italy
- Recruiting
- AOU di Ferrara (Ospedale Sant'Anna)
-
Principal Investigator:
- Simone Biscaglia, MD, PhD
-
Mestre, Italy
- Recruiting
- Cardiologia Ospedale Dell' Angelo
-
Principal Investigator:
- Marco Barbierato, MD, PhD
-
Milan, Italy
- Recruiting
- Humanitas Research Hospital
-
Principal Investigator:
- Antonio Mangieri, MD, PhD
-
Milan, Italy
- Recruiting
- Policlínico San Donato
-
Principal Investigator:
- Luca Testa, Md, PhD
-
Naples, Italy
- Not yet recruiting
- Pineta Grande Hospital
-
Principal Investigator:
- Arturo Giordano, MD, PhD
-
Novara, Italy
- Recruiting
- Ospedale Maggiore della Carita
-
Principal Investigator:
- Domenico D'Amario, MD, PhD
-
Verona, Italy
- Withdrawn
- AOU Verona
-
Vicenza, Italy
- Recruiting
- Cardiologia Ospedale San Bortolo
-
Principal Investigator:
- Flavio Ribichini, MD, PhD
-
-
-
-
-
Blaricum, Netherlands
- Recruiting
- Tergooi MC
-
Principal Investigator:
- Rutger van Bommel, MD, PhD
-
Breda, Netherlands
- Recruiting
- Amphia ziekenhuis
-
Principal Investigator:
- Martijn Meuwissen., MD, PhD
-
Dordrecht, Netherlands
- Recruiting
- Albert Schweitzer
-
Principal Investigator:
- Rohit Oemrawsing, MD, PhD
-
Rotterdam, Netherlands
- Recruiting
- Erasmus University Medical Center
-
Contact:
- Joost Daemen, MD, PhD
- Email: j.daemen@erasmusmc.nl
-
Utrecht, Netherlands
- Recruiting
- UMCU
-
Principal Investigator:
- Michiel Voskuil, MD, PhD
-
-
-
-
-
A Coruña, Spain
- Recruiting
- Hospital Univeritario A Coruna
-
Principal Investigator:
- Pablo Piñón Esteban, MD, PhD
-
Barcelona, Spain
- Recruiting
- Hospital Clinic
-
Principal Investigator:
- Manel Sabate, MD, PhD
-
Barcelona, Spain
- Recruiting
- Hospital del Mar
-
Principal Investigator:
- Beatriz Vaquerizo, MD, PhD
-
León, Spain
- Not yet recruiting
- Hospital Universitario de Leon
-
Principal Investigator:
- Maria Thiscal López Lluva, MD, PhD
-
Madrid, Spain
- Recruiting
- La Paz
-
Principal Investigator:
- Raul Moreno, MD, PhD
-
Madrid, Spain
- Recruiting
- Hospital Universitario de La Princesa
-
Principal Investigator:
- Fernando Rivero, MD, PhD
-
Oviedo, Spain
- Recruiting
- Hospital Universitario Central de Asturias
-
Principal Investigator:
- Pablo Avanzas, MD, PhD
-
Valladolid, Spain
- Recruiting
- Hospital Clinico Universitario de Valladolid
-
Principal Investigator:
- Ignacio Amat Santos, MD, PhD
-
-
-
-
-
Belfast, United Kingdom
- Withdrawn
- Royal Victoria Hospital
-
Brighton, United Kingdom
- Recruiting
- Royal Sussex County Hospital
-
Principal Investigator:
- James Cockburn, MD, PhD
-
Glasgow, United Kingdom
- Recruiting
- Golden Jubilee National Hospital
-
Principal Investigator:
- Damien Collison, MD, PhD
-
Oxford, United Kingdom
- Recruiting
- John Radcliffe Hospital
-
Principal Investigator:
- Adrian Banning, MD, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- The patient must be ≥18 years of age
- Presenting with silent ischemia, stable angina, or non-ST-elevation acute coronary syndrome (NSTE-ACS)
- Coronary artery disease with at least one native artery in which the stenosis severity is questionable (typically 30-80% stenosis)
- FFR assessment and vFFR assessment feasible
- The patient is willing and able to cooperate with study procedures and follow-up until study completion
- Subject is able to confirm understanding of risks, benefits and treatment alternatives and he/she provides informed consent prior to any protocol-related procedure, as approved by the appropriate Ethics Committee
Exclusion Criteria:
- ST-elevation myocardial infarction (STEMI) at presentation
- Cardiogenic shock or severe hemodynamic instability at the time of intervention (heart rate<50 beats per minute, systolic blood pressure <90mmHg) or use of left ventricular assist device
- Any target vessel with a distal Thrombolysis In Myocardial Infarction (TIMI) flow <3.
- Presence of thrombus in intermediate target lesion.
- Known untreated severe valvular heart disease
- Target lesion is located in or supplied by an arterial or venous bypass graft
- History of cardiac allograft transplantation
- Aorto-ostial lesions with an estimated diameter stenosis >50%
- Severe tortuosity precluding the acquisitions of 2 orthogonal projections of the target vessel with minimal overlap or foreshortening.
- Absolute contraindications or allergy that cannot be pre-medicated, to iodinated contrast or adenosine
- Non-cardiac co-morbidities with a life expectancy less than 1 year
- Currently participating in another trial that is not yet at its primary endpoint. The patient is not allowed to participate in another investigational device or drug study until the trial primary endpoint time point is achieved and may only be enrolled once in the study
- Women of childbearing potential who do not have a negative pregnancy test within 24 hours before the procedure
- Subject belongs to a vulnerable population (per Investigator's judgment) or subject unable to read or write
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: vFFR guided revascularization
|
3D-angio-based vessel FFR (CAAS, Pie Medical Imaging, Maastricht, The Netherlands) uses 3-Dimensional Quantitative Coronary Angiography (3D-QCA) for functional assessment of coronary stenosis.
vFFR is calculated using two angiographic views with at least 30 degrees difference in rotation/angulation to generate the 3D reconstruction of the coronary artery.
|
Active Comparator: FFR guided revascularization
|
Fractional flow reserve (FFR) is a technique used in coronary catheterization to measure pressure differences across a coronary artery stenosis (narrowing, usually due to atherosclerosis) to determine the likelihood that the stenosis impedes oxygen delivery to the heart muscle (myocardial ischemia)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of the composite of all-cause death, any myocardial infarction, or any revascularization
Time Frame: 1 year
|
Procedural myocardial infarction (MI) is adjudicated according to the ARC-2 consensus and spontaneous MI according to the 4th Universal definition of MI.
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Rate of patient-oriented composite endpoint (POCE) defined as all-cause death, any stroke, any myocardial infarction, and any revascularization
Time Frame: 1 year
|
1 year
|
Rate of device-oriented composite endpoint (DOCE) defined as the composite of cardiovascular death, target-vessel MI, clinically indicated repeat revascularization of the target lesion
Time Frame: 1 year
|
1 year
|
Rate of study-oriented composite endpoint (SOCE) defined as the composite of cardiovascular death, study-vessel or target vessel MI, or study-vessel or target vessel revascularization
Time Frame: 1 year
|
1 year
|
Rate of target-vessel failure defined as a composite of cardiac death, target vessel myocardial infarction, or clinically indicated target-vessel revascularization
Time Frame: 1 year
|
1 year
|
Rate of target-lesion failure defined as a composite of cardiac death, target vessel myocardial infarction, or clinically indicated target-lesion revascularization
Time Frame: 1 year
|
1 year
|
Rate of study-vessel failure defined as a composite of cardiac death, study vessel myocardial infarction, or clinically indicated study-vessel revascularization
Time Frame: 1 year
|
1 year
|
Rate of definite and probable stent thrombosis
Time Frame: 1 year
|
1 year
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Quality of life (QoL) using the Seattle Angina Questionnaire
Time Frame: 1 month and 1 year
|
1 month and 1 year
|
Procedural time
Time Frame: Baseline
|
Baseline
|
Total contrast volume
Time Frame: Baseline
|
Baseline
|
Fluoroscopy time
Time Frame: Baseline
|
Baseline
|
Radiation dose
Time Frame: Baseline
|
Baseline
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Joost Daemen, MD, PhD, Erasmus Medical Center
- Study Director: Ernest Spitzer, MD, European Cardiovascular Research Institute
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ECRI-15
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Artery Disease
-
Elixir Medical CorporationIstituto Clinico HumanitasActive, not recruitingCoronary Artery Disease | Chronic Total Occlusion of Coronary Artery | Multi Vessel Coronary Artery Disease | Bifurcation of Coronary Artery | Long Lesions Coronary Artery DiseaseItaly
-
Fundación EPICActive, not recruitingCoronary Artery Disease | Left Main Coronary Artery Disease | Left Main Coronary Artery Stenosis | Restenosis, CoronarySpain
-
Peking Union Medical College HospitalRecruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
Peking Union Medical College HospitalNot yet recruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
IGLESIAS Juan FernandoUniversity of BernNot yet recruiting
-
National Institutes of Health Clinical Center (CC)National Heart, Lung, and Blood Institute (NHLBI)CompletedCoronary Arteriosclerosis | Coronary Artery Disease (CAD) | Obstructive Coronary Artery DiseaseUnited States
-
Barts & The London NHS TrustImperial College London; Brunel UniversityNot yet recruitingCORONARY ARTERY DISEASE
-
Fundación EPICRecruitingCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Left Main Coronary Artery Disease | Coronary Artery StenosisSpain
-
Abbott Medical DevicesCompletedCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Chronic Total Occlusion of Coronary Artery | Coronary Restenosis | Coronary Artery Stenosis | Coronary Artery RestenosisBelgium
-
San Luigi Gonzaga HospitalRecruitingCoronary Disease | STEMI | Coronary Artery Ectasia | Right Coronary Artery Occlusion | Right Coronary Artery StenosisSpain, Italy
Clinical Trials on vFFR guided revascularization
-
Consorzio Futuro in RicercaActive, not recruitingMyocardial InfarctionSpain, Italy, Poland
-
Portuguese Society of CardiologyAbbott Medical DevicesUnknownCoronary Artery Disease | Valvular Heart DiseasePortugal
-
Sejong General HospitalSeoul St. Mary's Hospital; Pusan National University Hospital; Ulsan University... and other collaboratorsRecruiting
-
Medical University of GrazUnknownObstructive Coronary Artery DiseaseAustria, Hungary
-
Research Maatschap Cardiologen Rotterdam ZuidAbbott Medical DevicesRecruitingST Elevated Myocardial Infarction | Dual Antiplatelet TherapyNetherlands, Germany, Italy
-
Medical University of WarsawRecruitingAcute Coronary Syndrome | Chronic Coronary Syndrome | Non ST Segment Elevation Acute Coronary SyndromePoland
-
Medical University InnsbruckCompletedAcute Limb IschemiaCroatia, United Kingdom, Germany, Austria, France, Hungary, Moldova, Republic of, Netherlands, Serbia, Switzerland
-
University Hospital ErlangenCompletedEnd-stage Renal Disease | Critical Limb IschemiaGermany
-
Medical University of WarsawUniversity College, London; Queen Mary University of London; National Science...RecruitingAtherosclerosis | Chronic Coronary SyndromePoland
-
Rigshospitalet, DenmarkUniversitaire Ziekenhuizen KU Leuven; UMC Utrecht; Copenhagen Trial Unit, Center...Not yet recruitingCoronary Artery Disease